Schizophrenia Drugs Market Report 2026

The schizophrenia drugs market size has grown strongly in recent years. It will grow from $8.41 billion in 2025 to $8.92 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increased schizophrenia diagnosis, adoption of atypical antipsychotics, expansion of psychiatric hospitals, improved mental health awareness, growth in generic drugs.

The schizophrenia drugs market size is expected to see strong growth in the next few years. It will grow to $11.24 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rising mental health burden, growth in injectable therapies, increasing access to psychiatric care, digital mental health integration, expanding healthcare funding. Major trends in the forecast period include rising use of second and third generation antipsychotics, increasing adoption of long-acting injectable therapies, growing focus on long-term disease management, expansion of community-based mental healthcare, increased emphasis on treatment adherence.

Rising cases of schizophrenia are expected to drive the expansion of the schizophrenia drugs market in the coming years. Schizophrenia is a chronic mental disorder characterized by disrupted thoughts, perceptions, emotions, and behaviors, often leading to hallucinations and delusions. The increase in schizophrenia cases is linked to factors such as genetic susceptibility, environmental stress, substance abuse, and imbalances in brain chemistry. Schizophrenia drugs are used to manage symptoms effectively, lessening the disorder’s impact on patients’ daily lives and enhancing overall treatment outcomes. For example, in February 2024, the National Library of Medicine, a US-based biomedical library, reported that the prevalence of schizophrenia and related psychotic disorders ranged from 0.25% to 0.64% of the US population. Additionally, in January 2024, the British Columbia Schizophrenia Society, a Canada-based nonprofit organization, stated that schizophrenia is a leading cause of hospitalization for mental illnesses, accounting for 19.9% of general hospital admissions and 30.9% of stays in psychiatric facilities. Hence, the rising incidence of schizophrenia is expected to propel the growth of the schizophrenia drugs market.

Major companies operating in the schizophrenia drugs sector are concentrating on developing advanced therapies, such as oral medications for schizophrenia, to improve and simplify patient care and treatment results. Oral medications for schizophrenia are drugs administered by mouth to manage the disorder's symptoms, typically consisting of antipsychotics that help stabilize mood, thoughts, and perceptions. For example, in September 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Cobenfy, an innovative oral medication aimed at treating schizophrenia in adults. This pioneering drug combines xanomeline and trospium chloride, representing a significant shift from conventional antipsychotics by targeting cholinergic receptors rather than dopamine receptors. This novel mechanism may help alleviate symptoms such as delusions and disorganized thinking while minimizing the common side effects linked to older antipsychotic drugs, establishing Cobenfy as a promising alternative in the schizophrenia treatment field.

In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. The acquisition is anticipated to strengthen Bristol Myers Squibb's neuroscience portfolio by adding KarXT, a novel antipsychotic, and expanding its pipeline with potential treatments for schizophrenia, Alzheimer's disease, and other mental health disorders. Karuna Therapeutics is a US-based biopharmaceutical firm that develops drugs for schizophrenia.

Major companies operating in the schizophrenia drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co., Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., Sun Pharmaceutical Industries Ltd., AbbVie Inc., H. Lundbeck A/S, Cipla Ltd., Lupin Limited, Alkermes plc, Vanda Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Mylan NV, Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Holdings Inc., Lifegenix, Flagship Biotech International Pvt. Ltd.

North America was the largest region in the schizophrenia drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the schizophrenia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the schizophrenia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported APIs and injectable formulations used in schizophrenia treatment across acute and maintenance care settings. The impact is most pronounced in long acting injectable segments and hospital pharmacies, where supply continuity and cost control are critical. Regions such as North America and Europe have experienced higher input costs due to reliance on cross border pharmaceutical sourcing. Rising tariff related expenses have influenced treatment pricing, procurement planning, and inventory management in mental health care facilities. Tariffs have also encouraged domestic pharmaceutical manufacturing, expanded local formulation capacity, and strengthened regional drug supply chains over the long term.

The schizophrenia drugs market research report is one of a series of new reports that provides schizophrenia drugs market statistics, including schizophrenia drugs industry global market size, regional shares, competitors with a schizophrenia drugs market share, detailed schizophrenia drugs market segments, market trends and opportunities, and any further data you may need to thrive in the schizophrenia drugs industry. This schizophrenia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Schizophrenia medications are used to control the symptoms of schizophrenia, a long-term mental disorder that impacts thoughts, perceptions, emotions, and social interactions. By addressing chemical imbalances in the brain, especially dopamine and serotonin, these medications help lessen psychotic symptoms, regulate mood, and enhance cognitive abilities, supporting improved daily functioning and greater independence.

Second-generation, third-generation, and other drugs are the primary therapeutic classes used to treat schizophrenia. Second-generation antipsychotics, also known as atypical antipsychotics, manage schizophrenia by acting on dopamine and serotonin receptors, providing symptom relief while reducing the risk of movement-related side effects compared to first-generation medications. These drugs are available in various forms, including oral and injectable, and are distributed through multiple channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others.

The schizophrenia drugs market consists of sales of transdermal patches, liquid formulations, and adjunctive therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.